Halozyme Therapeutics, Inc. $HALO Shares Sold by Convergence Investment Partners LLC

Convergence Investment Partners LLC cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,085 shares of the biopharmaceutical company’s stock after selling 7,390 shares during the quarter. Convergence Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $1,473,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. CWM LLC lifted its stake in Halozyme Therapeutics by 2,136.0% during the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 22,813 shares during the period. Arbor Investment Advisors LLC acquired a new position in Halozyme Therapeutics during the third quarter valued at $1,316,000. Monument Capital Management purchased a new stake in Halozyme Therapeutics in the third quarter valued at $2,015,000. Pacer Advisors Inc. grew its position in Halozyme Therapeutics by 2,054.7% during the 3rd quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock worth $35,121,000 after purchasing an additional 456,649 shares during the period. Finally, Cardinal Capital Management acquired a new position in Halozyme Therapeutics in the third quarter valued at approximately $1,303,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HALO. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a research report on Tuesday, October 14th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $78.80.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer owned 708,719 shares in the company, valued at $48,844,913.48. This trade represents a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 41,398 shares of company stock worth $2,861,352. 2.40% of the stock is owned by corporate insiders.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer?term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt?on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell?side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi?year gains — useful context for longer?term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi?Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near?term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near?term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Halozyme Therapeutics Stock Down 2.2%

Halozyme Therapeutics stock opened at $71.71 on Monday. The stock’s fifty day moving average is $68.93 and its two-hundred day moving average is $68.52. The stock has a market cap of $8.43 billion, a PE ratio of 15.10, a P/E/G ratio of 0.31 and a beta of 0.94. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $79.50. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The business’s quarterly revenue was up 22.1% on a year-over-year basis. During the same quarter last year, the company earned $1.27 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.